SEC Form 4 reporting owner

Paulson Richard A.

Paulson Richard A. has filed 4 Form 4 transactions reported between February 5, 2026 and May 14, 2026, as President and CEO of Karyopharm Therapeutics Inc..

Name as filed: Paulson Richard A.

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$137K
2 lines
Companies
1
with Form 4 filings
Latest transaction
May 14, 2026
transaction date

Roles and reported holdings

  • KPTIKaryopharm Therapeutics Inc.
    Feb 5, 2026 – May 14, 2026

    President and CEO

    Held directly269,747 sh as of May 14, 2026 · Form 4

    24 months: $137K sold

Transaction history

All 4 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
May 14, 2026KPTIPresident and CEOOpen-market saleCode S · direct2,203$21K@ $9.50Form 4
May 13, 2026KPTIPresident and CEOGrant or awardCode A · direct4,920—Form 4
Mar 2, 2026KPTIPresident and CEOOpen-market saleCode S · direct12,361$116K@ $9.41Form 4
Feb 5, 2026KPTIPresident and CEOGrant or awardCode A · direct81,060—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.